Peptide Library

Human study PLS-00220

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

Other design · 41 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderlyregistry entry · NCT02245620 (COMPLETED, results posted, planned enrollment 41)

Design and participants

Design
Other design
Population
Elderly people with skeletal muscle mitochondrial dysfunction
Conditions
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Planned enrollment (registry)
41
Enrolled
41
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • Elamipretide (intervention) · elamipretide · Elamipretide (MTP-131, Bendavia) · Not reported assigned
  • Placebo (comparator) · Placebo · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Skeletal muscle function

unclear outcome · patient-important

  • No results reported.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • abstract only: Only the ClinicalTrials.gov registration is available. It has no abstract, no publication and no outcome results in the record.
  • selective reporting: The registry indicates results exist, but no outcome or adverse event data are provided in the record, so findings cannot be assessed.
  • small or imprecise: Actual enrollment was 41 participants across the elamipretide and placebo groups, which limits precision.
  • inappropriate population: Participants were elderly people with muscle mitochondrial dysfunction, not people with Barth syndrome or primary mitochondrial myopathy.
  • other: The record does not state whether allocation to elamipretide or placebo was randomized, nor whether it was blinded.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: NCT NCT02245620, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT02245620, registry (study_type and phases fields) · extracted by AI (automated, not verified by a person)
  • outcomes: NCT NCT02245620, title (study title) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT02245620, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT02245620, registry (conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).